These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 14662414)

  • 1. Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines.
    Shintani S; Li C; Mihara M; Yano J; Terakado N; Nakashiro K; Hamakawa H
    Oral Oncol; 2004 Jan; 40(1):43-51. PubMed ID: 14662414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
    Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A
    J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer.
    Shintani S; Li C; Mihara M; Terakado N; Yano J; Nakashiro K; Hamakawa H
    Int J Cancer; 2003 Dec; 107(6):1030-7. PubMed ID: 14601066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27(KIP1) and p15(INK4B) and induces G1 arrest in oral squamous carcinoma cell lines.
    Kiyota A; Shintani S; Mihara M; Nakahara Y; Ueyama Y; Matsumura T; Tachikawa T; Wong DT
    Oncology; 2002; 63(1):92-8. PubMed ID: 12187077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
    Teraishi F; Kagawa S; Watanabe T; Tango Y; Kawashima T; Umeoka T; Nisizaki M; Tanaka N; Fujiwara T
    FEBS Lett; 2005 Aug; 579(19):4069-75. PubMed ID: 16023108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells.
    Shintani S; Li C; Mihara M; Nakashiro K; Hamakawa H
    Cancer Lett; 2003 Nov; 201(2):149-55. PubMed ID: 14607328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
    Naruse I; Ohmori T; Ao Y; Fukumoto H; Kuroki T; Mori M; Saijo N; Nishio K
    Int J Cancer; 2002 Mar; 98(2):310-5. PubMed ID: 11857424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells.
    Jameson MJ; Taniguchi LE; VanKoevering KK; Stuart MM; Francom CR; Mendez RE; Beckler AD; Carlson HT; Thomas CY; Khalil AA
    J Oral Pathol Med; 2013 Apr; 42(4):332-8. PubMed ID: 23106397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.
    Solomon B; Hagekyriakou J; Trivett MK; Stacker SA; McArthur GA; Cullinane C
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):713-23. PubMed ID: 12573759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
    Barnes CJ; Bagheri-Yarmand R; Mandal M; Yang Z; Clayman GL; Hong WK; Kumar R
    Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
    Sgambato A; Camerini A; Faraglia B; Ardito R; Bianchino G; Spada D; Boninsegna A; Valentini V; Cittadini A
    J Cell Physiol; 2004 Oct; 201(1):97-105. PubMed ID: 15281092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo.
    Hara F; Aoe M; Doihara H; Taira N; Shien T; Takahashi H; Yoshitomi S; Tsukuda K; Toyooka S; Ohta T; Shimizu N
    Cancer Lett; 2005 Aug; 226(1):37-47. PubMed ID: 16004931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells.
    Matheny KE; Barbieri CE; Sniezek JC; Arteaga CL; Pietenpol JA
    Laryngoscope; 2003 Jun; 113(6):936-9. PubMed ID: 12782800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
    Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
    Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cepharanthine exerts antitumor activity on oral squamous cell carcinoma cell lines by induction of p27Kip1.
    Harada K; Supriatno ; Yamamoto S; Kawaguchi S; Yoshida H; Sato M
    Anticancer Res; 2003; 23(2B):1441-8. PubMed ID: 12820407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
    Ciardiello F; Caputo R; Borriello G; Del Bufalo D; Biroccio A; Zupi G; Bianco AR; Tortora G
    Int J Cancer; 2002 Mar; 98(3):463-9. PubMed ID: 11920601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status.
    Suzuki T; Nakagawa T; Endo H; Mitsudomi T; Masuda A; Yatabe Y; Sugiura T; Takahashi T; Hida T
    Lung Cancer; 2003 Oct; 42(1):35-41. PubMed ID: 14512185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.